Evidence map›Paper›PMID 30935262›Full record

ReviewThe Journal of dermatological treatment2020

Off-label studies on apremilast in dermatology: a review.

Nolan J Maloney, Jeffrey Zhao, Kyle Tegtmeyer, Ernest Y Lee, Kyle Cheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of dermatological treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nolan J MaloneyDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9722-5673
Jeffrey ZhaoNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-7046-5434
Kyle TegtmeyerNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-5828-6991
Ernest Y LeeDavid Geffen School of Medicine at UCLA, UCLA-Caltech Medical Scientist Training Program, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-5144-2552
Kyle ChengDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Dermatology Scientist Training ProgramT32AR071307 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2017 to 2021
$1.1M
NIAMS NIH HHS T32 AR071307NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alopecia AreataAnti-Inflammatory Agents, Non-SteroidalArthritis, PsoriaticBehcet SyndromeHidradenitis SuppurativaHumansNauseaOff-Label UseRandomized Controlled Trials as TopicThalidomideAnti-Inflammatory Agents, Non-SteroidalapremilastThalidomideApremilastoff-labelpsoriasis

Identifiers

PMID30935262
PMCPMC6774908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.